SCHEMBL1582239

SCHEMBL1582239

CO[C@@H]1[C@@H]2O[Si](C(C)(C)C)(C(C)(C)C)OC[C@H]2O[C@H]1n1cnc2c(NC(=O)C(C)C)nc(NC(=O)C(C)C)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK5 Q00535 3/20 0.38
▸ CDK5R1 Q15078 3/20 0.38
▸ CYP1A2 P05177 1/20 0.34
▸ HTR1A P08908 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ ADRB3 P13945 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PTGS2 P35354 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ PDE3A Q14432 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ACHE P22303 3/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ ADORA3 P0DMS8 3/20 0.33
▸ ADORA2A P29274 3/20 0.33
▸ ADORA1 P30542 3/20 0.33
▸ NT5E P21589 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403262 0.92 ADORA2A (0.38) ADORA3ADORA2AADORA1
SCHEMBL6362480 0.79 ADORA2A (0.37) ADORA3ADORA2AADORA1
SCHEMBL7197488 0.79 ADORA2A (0.37) ADORA3ADORA2AADORA1
SCHEMBL1582124 0.76 HINT1 (0.39) ADORA3ADORA2ANT5E
SCHEMBL5963062 0.75 MEN1 (0.53) ADORA3ADORA2AADORA1MEN1KMT2A
SCHEMBL20547879 0.73 STING1 (0.35) PDE3AALDH1A1MEN1KMT2A
SCHEMBL27419759 0.71 ADORA2A (0.36) ALDH1A1ADORA3ADORA2AADORA1MEN1
SCHEMBL16871804 0.69 RXFP1 (0.39) CYP1A2HTR1ACYP2D6ADRB3PDE4A
SCHEMBL8164945 0.69 ADORA3 (0.54) CDK5CDK5R1ADORA3ADORA2AADORA1
SCHEMBL12803795 0.69 PDE4A (0.41) CYP1A2HTR1ACYP2D6ADRB3PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313752-B1 METHODS FOR SYNTHESIZING NUCLEOSIDE DERIVATIVES RIBOZYME PHARM INC (US) 2011-04-20 — — EP disclosed
US-20050059817-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives SIRNA THERAPEUTICS, INC. (US) 2005-03-17 — — US disclosed
US-6686463-B2 FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING SIRNA THERAPEUTICS, INC. 2004-02-03 — — US disclosed
US-20020150936-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives RIBOZYME PHARMACEUTICALS, INC. 2002-10-17 — — US disclosed
US-20020120129-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives RIBOZYME PHARMACEUTICALS, INC. 2002-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059817-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives PNP, NSUN2, NT5C3B CDK5 564/4885CDK5R1 1341/4885CYP1A2 4016/4885
US-20020120129-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives PNP, NSUN2, NT5C3B CDK5 284/4885CDK5R1 835/4885CYP1A2 3625/4885
US-20020150936-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives PNP, NSUN2, NT5C3B CDK5 340/4885CDK5R1 986/4885CYP1A2 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback